文献速递胸部肿瘤

帕博利珠单抗联合或不联合铂类化疗一线治疗PD-L1≥50%晚期NSCLC:PERSEE随机III期试验

Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020).
PubMed 文献 · Ann Oncol · 2026-10-25

PERSEE研究为多中心III期试验,纳入321例初治晚期NSCLC且PD-L1≥50%患者,随机接受帕博利珠单抗联合化疗或帕博利珠单抗单药。中位随访38.7个月,联合组中位PFS显著延长(16.1 vs 6.9个月,HR 0.56,P<0.001),中位OS为50.2 vs 29.9个月(HR 0.77)。联合组≥3级治疗相关不良事件发生率更高(54% vs 19%)。

要点

  • 联合化疗显著延长PFS,HR 0.56,P<0.001。
  • 中位OS联合组50.2个月 vs 单药29.9个月,HR 0.77。
  • 联合组≥3级治疗相关不良事件54% vs 19%。

核心结论

  • 在初治晚期NSCLC且PD-L1≥50%患者中,帕博利珠单抗联合铂类化疗较单药显著延长PFS。

研究设计与样本

  • 多中心III期随机试验(PERSEE,NCT04547504),321例初治IV期或不可切除III期NSCLC且PD-L1≥50%患者随机1:1分配。
  • 联合组接受帕博利珠单抗(200 mg每3周,最多35周期)联合4周期诱导化疗,按脑转移和組織学分层。
  • 非鳞癌患者化疗为顺铂或卡铂(AUC 5)联合培美曲塞,后续帕博利珠单抗-培美曲塞维持;鳞癌患者为卡铂(AUC 6)联合紫杉醇,后续帕博利珠单抗维持。

主要发现

  • 中位随访38.7个月,联合组中位PFS 16.1个月(95%CI 11.0-34.1)vs 单药组6.9个月(95%CI 5.5-9.3),HR 0.56(95%CI 0.43-0.74),P<0.001。
  • 中位OS联合组50.2个月 vs 单药组29.9个月,HR 0.77(95%CI 0.56-1.05)。
  • ≥3级治疗相关不良事件发生率联合组54% vs 单药组19%;≥3级免疫相关不良事件两组均为13%。

关键数值与推荐

  • 主要终点为盲法中心依据RECIST v1.1评估的PFS,联合组显著优于单药组。
  • 关键次要终点包括OS、客观缓解率、缓解持续时间和安全性。

临床怎么用

  • 对于PD-L1≥50%且无驱动基因改变的晚期NSCLC,帕博利珠单抗联合铂类化疗可作为一线治疗选择,但需权衡更高的≥3级不良事件风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pembrolizumab, alone or combined with platinum-based chemotherapy, is a standard first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) without actionable oncogenic alterations and with high programmed death-ligand 1 (PD-L1) expression. We conducted a head-to-head comparison of these two treatment strategies. METHODS: In this multicenter, phase III trial (PERSEE, NCT04547504), adult patients with treatment-naïve stage IV or unresectable stage III NSCLC not amenable to definitive radiotherapy and PD-L1 expression ≥50% were randomly (1:1) assigned to receive pembrolizumab (200 mg every 3 weeks, for up to 35 cycles) or pembrolizumab in combination with four cycles of induction chemotherapy, stratified according to the presence of brain metastases and histologic subtype. Patients with non-squamous histology received cisplatin or carboplatin (AUC 5) plus pemetrexed, followed by pembrolizumab-pemetrexed maintenance; patients with squamous histology received carboplatin (AUC 6) plus paclitaxel, followed by pembrolizumab maintenance. The primary endpoint was progression-free survival (PFS), assessed by blinded central review according to RECIST v1.1. Key secondary endpoints included overall survival (OS), objective response rate, duration of response, and safety. RESULTS: A total of 321 patients underwent randomization, with 160 assigned to pembrolizumab plus chemotherapy and 161 to pembrolizumab monotherapy. At a median follow-up of 38.7 months, median PFS was significantly longer with combination therapy than with monotherapy (16.1 months [95% CI, 11.0-34.1] vs. 6.9 months [95% CI, 5.5-9.3]; hazard ratio (HR), 0.56; 95% CI, 0.43-0.74; P<0.001). Median OS was 50.2 months versus 29.9 months, respectively (HR, 0.77; 95% CI, 0.56-1.05). Grade ≥3 treatment-related adverse events occurred in 54% and 19% of patients, respectively; grade ≥3 immune-related adverse events occurred in 13% of patients in each group. CONCLUSIONS: Among patients with treatment-naïve advanced NSCLC and high PD-L1 expression, the addition of platinum-based chemotherapy to pembrolizumab significantly prolonged PFS compared with pembrolizumab monotherapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Descourt R, Mogenet A, Consigny M, et al. Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020). Ann Oncol. 2026. PMID: 42927854. doi:10.1016/j.annonc.2026.10.108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。